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A B S T R A C T
Purpose
To establish the performance characteristics of annual transvaginal ultrasound and serum CA125
screening for women at high risk of ovarian/fallopian tube cancer (OC/FTC) and to investigate the
impact of delayed screening interval and surgical intervention.
Patients and Methods
Between May 6, 2002, and January 5, 2008, 3,563 women at an estimated  10% lifetime risk of
OC/FTC were recruited and screened by 37 centers in the United Kingdom. Participants were
observed prospectively by centers, questionnaire, and national cancer registries.
Results
Sensitivity for detection of incident OC/FTC at 1 year after last annual screen was 81.3% (95% CI,
54.3% to 96.0%) if occult cancers were classified as false negatives and 87.5% (95% CI, 61.7%
to 98.5%) if they were classified as true positives. Positive and negative predictive values of
incident screening were 25.5% (95% CI, 14.3 to 40.0) and 99.9% (95% CI, 99.8 to 100)
respectively. Four (30.8%) of 13 incident screen-detected OC/FTCs were stage I or II. Compared
with women screened in the year before diagnosis, those not screened in the year before
diagnosis were more likely to have  stage IIIc disease (85.7% v 26.1%; P  .009). Screening
interval was delayed by a median of 88 days before detection of incident OC/FTC. Median interval
from detection screen to surgical intervention was 79 days in prevalent and incident OC/FTC.
Conclusion
These results in the high-risk population highlight the need for strict adherence to screening
schedule. Screening more frequently than annually with prompt surgical intervention seems to
offer a better chance of early-stage detection.
J Clin Oncol 30. © 2012 by American Society of Clinical Oncology
INTRODUCTION
Approximately 10%1-3 of ovarian cancers (OCs) are
a result of familial/genetic predisposition, predomi-
nantly germline mutations in BRCA1 and BRCA2
andmismatch repair genes inLynch syndrome(LS).
The risk of OC (until age 70 years) varies between
3.4% to 33% in LS,4-6 11% to 37% in BRCA2 carri-
ers, and 39% to 65% in BRCA1 carriers.7-10
Given the poor survival associated with OC,11
women with a known predisposing mutation or
strong family history are offered risk-reducing bilat-
eral salpingo-oophorectomy (RRSO) to prevent
OC/fallopian tube cancers (FTCs).12 In premeno-
pausal women, RRSO halves the risk of expected
breast cancers13 but results in infertility and prema-
ture menopause, with associated increased cardio-
vascular14 andosteoporosis15 risks.Delaying surgery
until age 50 years carries OC/FTC risks of 15%
to 27% in BRCA1 and 0.4% to 4% in BRCA2
carriers.7-9,16 Screening might enable women to
delay RRSO until menopause.
OC/FTC survival inversely correlates with
stage.17 Although improved medium-term survival
has been shown with general population screen-
ing,18 with a high proportion of early-stage cancers
detected in the prevalence screen of an ongoing
trial,19 recently another trial found no mortal-
ity benefit.20
Random assignment to a nonscreening arm
is unacceptable to high-risk women and clini-
cians (United Kingdom Familial Ovarian Cancer
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Screening Study [UK FOCSS] consensus meeting, London, United
Kingdom, 2004). Best evidence in this populationwill probably come
from prospective cohort studies. Here we present the largest such
study to date, to our knowledge, to define screening performance
characteristics and investigate the impact of delayed screening interval
and surgical intervention.
PATIENTS AND METHODS
BetweenMay 6, 2002, and January 5, 2008, 3,563 women at an estimated mini-
mum 10% lifetimeOC risk were recruited, and data on screening and outcomes
were collected prospectively. The study was designed to estimate sensitivity
within 10%(expected 95%CI), assuming 0.5%annualOC incidence.
Entry Criteria
The inclusion criteria originally defined a minimum 10% lifetime OC
risk (Appendix, online only) on the basis of family history or predisposing
mutations, includingLS-associatedmutations.OCin the familywasdefinedas
epithelial OC, FTC, or primary peritoneal cancer (PPC). Borderline and non-
epithelial OC were excluded. Women were excluded if they had undergone
bilateral salpingo-oophorectomy,were age35years, orwereparticipating in
other OC screening trials.
Recruitment
After ethical approval (EasternMulticentre Research Ethics Committee
97/5/007), women were recruited by specialist nurses, clinical geneticists, or
gynecologists at 37 regional centers in the United Kingdom. Before consent-
ing, women were counseled that RRSO was recommended management,
being the only method of preventing OC/FTC. The limitations of screening
were highlighted. Documentation (death certificates, histopathology reports)
of relevant familial cancers was required, and eligibility was confirmed by the
coordinating center (CC). Recruiting centers forwarded screening results to
the CC for database entry (UK FOCSS Trial Management System, developed
inMS Visual Basic 6 and Classic ASP 3, Microsoft SQL Server 2000).
Screening
Phase I of UK FOCSS comprised annual transvaginal ultrasound scans
(TVSs) and serum CA125 measurements, arranged and performed locally.
Annual scans were performed by experienced National Health Service ultra-
sonographers, and follow-up scans for abnormalities were performed by ex-
pert gynecologists or radiologists. Where practical, scans were scheduled for
menstrual cycle days 3 to 6. Collaborating centers were asked to complete
datasheets describing ovarian volume andmorphology, which were classified
according to predetermined criteria (Appendix, online only). Guidelines for
management of results were provided (Appendix Fig A1, online only), but
management remained at thediscretionof collaborating gynecologists. Serum
CA125wasmeasured using preferred assays at collaborating clinical laborato-
ries. We recommended cutoffs of 35 and 30 IU/mL in premenopausal and
postmenopausal women, respectively.21 Between 2007 and 2009, phase II
screening (once every 4 months) was introduced in response to concerns22
about the ability of annual screening to detect early-stage disease. Phase II is
currently in follow-up and will be reported separately.
Documentation of Surgical Procedures and Diagnoses
Wheneverwomenunderwent salpingo-oophorectomy, theCCobtained
documentation explaining surgical indication, whether CA125 and/or scan
results had prompted surgery, the operation note, and histopathology and
cytopathology reports. These were reviewed by a gynecologic oncologist
(A.N.R.) andpathologist (E.B.,N.S.). Serial sectioningof tubes/ovarieswasnot
mandatory for RRSO specimens.
Criteria for Screening Performance Characteristics
Womenundergoing salpingo-oophorectomywereonlyclassifiedashav-
inghadRRSOif theywereasymptomatic andhadnormal screening tests in the
year before surgery and if the recruiting center indicated RRSO as the reason
for withdrawal from the study. Cases in which abnormal screening results
prompted surgery were true positive if invasive epithelial OC/FTC was diag-
nosed. All other diagnoses (including borderline/benign ovarian tumors) re-
sulting from surgery prompted by abnormal test results were false positive.
Cases in which a nonconcerning test result (eg, simple ovarian cysts, tran-
siently raisedCA125) had contributed to the decision toundergo surgerywere
classified as screening-related surgery to provide estimates of likely additional
surgeries in any future screening program. True-negative patients were those
inwhomthe last screenwasnormal, andnodiagnosis ofOC/FTCwasmade in
the subsequent 365 days. Prevalent cases were those in which patients were
diagnosed at first screen. Incident cases were those in which patients were
diagnosed after subsequent screens.
Cancers diagnosed 365 days after a woman’s last screen are reported
but not included in the analyses of annual screening performance. PPC (de-
fined according to recognized pathologic criteria23) is unlikely to be amenable
to early-stage detection using current techniques; however, data are presented
both including and excluding PPC from the screening performance analysis.
Interval cancers (false negatives) were those presenting clinically
 365 days after the last screen. Occult cancers found in RRSO specimens
 365 days after the last annual screen can be classified as either false
negative or true positive, because they might have been missed or detected
at the next annual screen had RRSO not been performed. We therefore
report screening performance using both these scenarios, on the assump-
tion that the true sensitivity of screening in a population not undergoing
RRSO falls between these two estimates.
Follow-Up
Collaboratorsnotified theCCwhenwomenwithdrew fromthe study. In
December 2006, all women were invited to join phase II of the study and to
confirm they still had one or more ovaries/fallopian tubes. All women were
flagged with the relevant national cancer registry (National Health Service
Information Centre for Health and Social Care, General Registrar Office for
Scotland, and Northern Ireland Cancer Registry).
For womenwhowithdrew, data was censored 365 days after withdrawal
date. Details of OC/FTCs occurring after censoring are reported but not
Table 1. Indication for Inclusion and Mutation Status of Study Participants
Indication for Inclusion or Mutation Status No. %
Indication for Inclusion
Known mutation in family and/or proband 867 24.4
Breast/ovarian family history; no known mutation 1,499 42.1
Ovarian only family history; no known mutation 889 25.0
Lynch syndrome family history; no known mutation 25 0.7
Not fitting standard inclusion criteria but deemed
high risk by recruiting center and study clinical
geneticist (J.M.) 283 7.9
Total 3,563 100
Mutation status of proband at censor date
BRCA1 282 7.9
BRCA2 250 7.0
BRCA1 and BRCA2 6 0.2
MLH1 28 0.8
MSH2 33 0.9
MSH6 4 0.1
PMS1 0 0.0
PMS2 0 0.0
Tested negative 322 9.0
Tested but result pending 109 3.1
Untested 2,529 71.0
Total 3,563 100
NOTE. Documentation (death certificates or histopathology reports) of rele-
vant cancers in the family was required. This was available for 63.9% of
women included for reasons other than a predisposing mutation in them-
selves or first-degree relative.
Nine were possible Lynch syndrome families, and 271 were breast/ovarian
cancer families.
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included in the analyses of annual incidence or screening performance. OC/
FTCs diagnosedwithin 365 days of awoman’s last screenwere included in the
analyses. Of women in phase I of UK FOCSS, 66.2% transferred to phase II of
the study and subsequently underwent CA125 testing once every 4 months
and annual TVS. For thesewomen, withdrawal date fromphase I was the date
of their first screen on phase II (ie, 4 months after their last annual phase I
screen), and data were censored 365 days after withdrawal date. Because no
cancers occurred within 1 year of a woman transferring to phase II, sensitivity
was not artificially increased by the introduction of screening once every
4months.
To investigate potentially avoidable delays (which could influence stage
atdetection),weanalyzed screeningdelays inwomendiagnosedwithOC/FTC
and the interval between abnormal test results and surgical investigation.
Detection screens were defined as an abnormal TVS and/or elevated CA125
result found at an annual screen leading to surgery/diagnostic biopsy resulting
in diagnosis of OC/FTC. Delays in annual screens were defined as any detec-
tion screen (CA125 or TVS) performed  365 days after previous normal
annual screen.Delaywas calculatedasdaysbetweendetection screenandprior
normal annual screenminus 365. Interval from screen to diagnosis was calcu-
lated to the date of surgery/diagnostic biopsy. Composite delay was calculated
as the sum of screening delay and screen to diagnosis interval. To investigate
any effect of delayed screening,we analyzed International FederationofGyne-
cology andObstetrics stage, optimal debulking ( 1 cm residual disease), and
overall and disease-specific survival from diagnosis (irrespective of whether
cancers were screen detected), comparing women screened in the year before
diagnosis with those not screened in the year before diagnosis. We excluded
LS-associated cases from these analyses to avoid contaminating the predomi-
nant BRCA-associated cases.
RESULTS
The median age of participants at recruitment was 44.6 years (range,
35 to 81 years). Table 1 lists indications for inclusion. One thousand
thirty-four women (29.0% of the cohort) had undergone mutation
testing before censoring. Six hundred threewomen (65.2%of those in
whom test results were known; 16.9% of the cohort) were known
mutation carriers.
The studyaccumulated11,366women-yearsof screening (mean,
3.2 years per woman). Figure 1 shows the flow of participants. Al-
though 182 women (5.1%) were lost to direct follow-up by the CC,
they remainedflaggedby the cancer registries. The commonest reason
for withdrawal was RRSO (14.3% of the study population), but an
additional 4.2%withdrew because they were subsequently found not
to carry their family’s predisposingmutation.
Index Cancers
Table 2 shows cancers occurring during screening and follow-up
according towhether cancersweredetected at prevalenceor incidence
Moved 
away
(n = 25; 2.1%)
Not 
eligible*
(n = 18; 1.5%)
Negative test 
for family
mutation
(n = 148; 12.3%)
Died without
OC, FTC,
or PPC
(n = 20; 1.7%)
Surgery
(n = 637; 52.8%)
OC, FTC, or PPC
(n = 33; 5.2%)
Died as a result 
of disease
 (n = 11)
Participant
choice
(n = 172; 14.3%)
Center not 
in phase II
(n = 4; 0.3%)
Recruited to
UK FOCSS phase I
(N = 3,563)
Withdrawn 
(n = 1,206; 33.8%)
Transferred to UK FOCSS phase II
(n = 2,357; 66.2%)
Lost to follow-up† 
(n = 58; 4.8%)
Nonresponders† 
(n = 124; 10.3%)
RRSO
 (n = 508; 79.7%)
OC, FTC, or PPC
All alive
(n = 4; 0.8%)
Reason
pending‡
 (n = 34; 5.3%)
Screening-
related surgery
 (n = 4; 0.6%)
Surgery for
unrelated 
reason
 (n = 6; 0.9%)
False-positive 
surgery 
(n = 52; 8.2%)
Fig 1. Flow of participants through study. All percentages refer to proportion of population defined in preceding row. UK FOCSS, United Kingdom Familial Ovarian
Cancer Screening Study; FTC, fallopian tube cancer; OC, ovarian cancer; PPC, primary peritoneal cancer; RRSO, risk-reducing salpingo-oophorectomy. (*) Ineligible on
basis of new information regarding diagnoses in family history becoming available subsequent to recruitment. (†)Lost to follow-up: unable to establish current
whereabouts; nonresponders: failed to respond despite confirmation of correct contact details. (‡) Reason for surgery pending, but known not to have had OC, FTC,
or PPC.
UK FOCSS Annual Screening Results
www.jco.org © 2012 by American Society of Clinical Oncology 3
128.40.156.97
Information downloaded from jco.ascopubs.org and provided by at UCL Library Services on December 5, 2012 from
Copyright © 2012 American Society of Clinical Oncology. All rights reserved.
Table 2. Ovarian, Tubal, and Peritoneal Cancers Occurring During Screening and Follow-Up
FIGO Stage
No. of
Patients
Tumor
Gene
Mutation
Age
(years)
CA125 at
Diagnosis
(u/mL)
Imaging
Modalitya
Delay in
Annual
Screen at
Detection
(days)b
Interval
Between
Abnormal
Test and
Surgery
(days)
Composite
Interval
(days)cSubstage Grade Histotype Site
Prevalent
cancers 9
I 5 Ia G3 Clear cell OC MSH2 35 24 TVS NA 141 NA
Ic G3 Serous OC MLH1 60 128 TVS NA 36 NA
Ic G3 Serous OC BRCA2 51 22 TVS NA 126 NA
Ic G2 Serous FTC BRCA1 55 21 TVS NA 20 NA
Ic G3 Clear celld OC MSH2 49 94 TVS NA 36 NA
II 1 IIb G3 Serous FTC BRCA1 47 103 TVS NA 79 NA
III 3 IIIa G3 Serous OC BRCA2 53 48 TVS NA 96 NA
IIIb G3 Serous OC BRCA1 48 88 TVS NA 92 NA
IIIc G3 Serous OC BRCA1 57 223 TVS NA 74 NA
Incident screen-
detected
cancers 13
I 2 Ia G1 Endometrioid OC Untestede 45 21 TVS 49 19 68
Ia G2 Serous FTC BRCA1 43 11 TVS 52 79 27
II 2 IIc G3 Adenocarcinoma/
endometrioid
OC BRCA1 55 39 TVS 737 138 875
IIc G3 Serous OC BRCA1 52 192 TVS 231 21 252
III 9 IIIa G3 Endometrioid OC BRCA1 45 124 TVS 27 184 211
IIIb G2 Serous OC BRCA1 46 73 TVS 1 69 68
IIIb G2 Serous OC Untestedf 42 45 TVS 102 107 209
IIIb G3 Serous OC BRCA1 48 3,874 TVS 50 15 35
IIIb G3 Adenocarcinoma/
mucinous
OC/FTC BRCA1 57 4 TVS 30 147 177
IIIc G2 Endometrioid OC BRCA1 52 246 TVS 78 20 98
IIIc G3 Serous/
endometrioid
OC/FTC BRCA1 49 323 TVS 98 32 130
IIIc G3 Serous FTC BRCA2 60 17 TVS 236 177 413
IIIc G3 Serous FTC VUSg 58 166 TVS 6 96 102
FIGO Stage
No. of
Patients
Tumor
Gene
Mutation
Age
(years)
CA125 at
Diagnosis
(u/mL)
Imaging
Modalitya
Last
Screen to
Diagnosis
Interval
(days) PresentationSubstage Grade Histotype Site
Screen-negative
cancers 8
I 1 Ich G3 Serous/
endometrioid
OC BRCA1 67 Not donei Not donei 221 Ovarian cyst torsion
III 5 IIIc G3 Serous OC BRCA1 65 582 CT 382 GI symptoms
IIIc G3 Serous OC BRCA1 67 527 TVS 421 GI symptoms
IIIc G3 Serous FTC/OC BRCA1 74 278 TVS 1,369 Abdominopelvic pain
IIIc G3 Serous OCj BRCA1 60 724 TVS 593 Postmenopausal bleeding
IIIc G3 Serous OC BRCA2 62 550 CT 1,073 Breast cancer restaging
IV 2 IV G2 Serous OC BRCA1 62 1,513 TVS 327 Postmenopausal bleeding
IV G3 Small cell OC BRCA2 58 560 CT 982 GI symptoms
Occult and
primary
peritoneal
cancers 7
I 2 Ia G2 Serous FTC BRCA1 53 Not donek Not donek 76 Occult found at RRSO
Ic G3 Serous/mucinous OC BRCA1 38 Not done Not done 539 Occult found at RRSO
II 1 IIc G2 Serous OC/FTC BRCA1 60 Not donel Not donel 106 Occult found at RRSO
III 4 IIIb G3 Serous Peritoneal BRCA1 61 404 CT 497 Screen detected
IIIc G2 Serous Peritoneal Untestedm 60 1173 CT 255 GI symptoms
(continued on following page)
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screens, screen negative, occult, or PPC. Twenty-six primary invasive
epithelialOC/FTCandonePPCwere observedduring 11,366women
screen–years before censoring (annual OC/FTC/PPC incidence,
0.24%).Anadditional 10 cancersoccurredbeyondcensoring365days
after a last screen (median, 539 days; range, 382 to 1369).
Twenty-nine (78.4%) of 37 cancers contained serous carcinoma;
the remainder were predominantly endometrioid. Two clear-cell car-
cinomas occurred in LSmutation carriers. Themedian age of diagno-
sis was 53 years (range, 35 to 74 years), and 15 (40.5%) of 37 were
premenopausal. Thirty-three (89.2%) of 37 cancers occurred in
pathogenicmutation carriers. Of these, 24 (72.7%) were BRCA1 mu-
tation carriers, six (18.2%) were BRCA2 mutation carriers, and three
(9.1%)were carriers of LSmutations MLH1 (one patient) and MSH2
(two patients). An additional woman had a BRCA1 variant of un-
known significance. Three women (8.1% of all OC/FTC/PPC) had
not undergonemutation testing (Table 2). Twenty-two (66.7%) of 33
womenwithapathogenicmutationknewtheirmutation statusbefore
diagnosis of OC/FTC/PPC, and 13 women (35.1%) with OC/FTC/
PPC had a prior diagnosis of breast cancer (11 women) or ductal
carcinoma in situ (two women).
Of prevalent OC/FTCs, six (66.7%; 95%CI, 35.1% to 88.2%) of
nine were International Federation of Gynecology and Obstetrics
stage I or II. Four (30.8%; 95% CI, 12.4% to 58.0%) of 13 incident
screen-detected OC/FTCs were stage I or II. When LS cases were
excluded, six (85.7%; 95%CI, 42.1% to 99.6%) of seven OC/FTCs in
women not screened in the year before diagnosis were stage IIIc or
higher, compared with six (26.1%; 95% CI, 10.2% to 48.4%) of 23
women who were screened in the year before diagnosis (Fisher’s test
P .009).Four (57.1%;95%CI,18.4%to90.1%)of sevenwomennot
screened in the year before diagnosis underwent optimal debulking
surgery (residual 1 cm), compared with 21 (91.3%; 95%CI, 72.0%
to98.9%)of23womenwhowere screened in theyearbeforediagnosis
(Fisher’s test P  .068). Both mean overall and disease-specific sur-
vival (toMarch 31, 2011) were 48.4months (95%CI, 39.4 to 57.4) in
womennot screened in the year before diagnosis, comparedwith 71.9
months (95%CI, 60.7 to 83.2) in those whowere screened in the year
beforediagnosis (log-rank [Mantel-Cox]P .233); all deaths resulted
fromOC/FTC.
Screening Performance
Annual screening performance characteristics are listed in Table
3. Two women were diagnosed with interval OCs within 365 days of
normal screens. Four women had occult OC/FTC/PPC found at
RRSO (prevalence, 0.8%; 95% CI, 0.2% to 2.0%). Two of these were
within 365 days of normal screens and were includable as false nega-
tives or true-positives in the sensitivity analysis. Two of the eight
screen-negative OC/FTCs were diagnosed  365 days of an annual
screen and sowere included as false negatives. Fifteen (68.2%)of 22 of
all screen-detected cancers had a raised CA125 at detection (median,
80.5 IU/mL; range, 4 to3,874)according to thepredeterminedcutoffs.
All screen-detected cancers had abnormal TVS at detection.
Fifty-two women (1.5%) underwent false-positive surgery
prompted at least in part by abnormal screening test results. Five of
these women (9.6%) had raised CA125 alone, 43 (82.7%) had a sus-
picious scanalone, and four (7.7%)hadabnormal results inboth tests.
Four (7.7%) of these 52 women had gynecologic pathology (one
benign teratoma,onemucinousborderline tumor,one serousborder-
line tumor, one fibroid). All these lesions were detected on TVS, and
only the fibroid had raised CA125. An additional four women (0.1%)
underwent surgery after equivocal ultrasound results or transient
nonconcerning small rises in CA125. Because documentation from
the collaborating center indicated that test results had contributed to
the woman’s decision to undergo RRSO, these cases were classified as
screening-related surgery.
Table 2. Ovarian, Tubal, and Peritoneal Cancers Occurring During Screening and Follow-Up (continued)
FIGO Stage
No. of
Patients
Tumor
Gene
Mutation
Age
(years)
CA125 at
Diagnosis
(u/mL)
Imaging
Modalitya
Last
Screen to
Diagnosis
Interval
(days) PresentationSubstage Grade Histotype Site
IIIc G2 Serous Peritoneal BRCA1 40 Not done Not done 411 Occult found at RRSO
IIIc G3 Serous Peritoneal BRCA2 57 613 CT 678 CA125 taken
approximately 1 year
after RRSO
Abbreviations: CT, computed tomography (instead of ultrasound); FTC, fallopian tube cancer; NA, not applicable; OC, ovarian cancer; RRSO, risk-reducing
salpingo-oophorectomy; TVS, transvaginal ultrasound; VUS, variant of unknown significance.
aImaging was abnormal in all patients for whom it was performed.
bNegative number denotes annual screen scheduled early.
cSum of delay in annual screening and interval from abnormal test to surgery (negative number results from annual screen scheduled early).
dOccurring against a background of endometriosis.
eConfirmed diagnoses of bowel cancer in paternal cousin (at age 61 years), paternal grandmother (at age 50 years), and sister (at age 51 years, with synchronous
OC) and possibly breast cancer in maternal cousin (at age 35 years). Family has tested negative for BRCA1, BRCA2, and immunohistochemical Lynch syndrome
markers. Patient herself had previous unilateral oophorectomy for endometriosis.
fConfirmed OC diagnoses in mother at age 52 years and maternal grandmother at age 73 years.
gVUS in BRCA1 (5313-12 GA).
hIncompletely staged.
iLast screen 221 days before emergency surgery; ovaries not seen on scan because of bowel gas; no CA125 taken; prior screen (scan and CA125) normal 574 days
before presentation.
jThis patient had a synchronous stage II grade 2 endometrioid endometrial cancer.
kLast screen 76 days before RRSO; CA125, 18 u/mL; normal scan.
lLast screen 106 days before RRSO; CA125, 21 u/mL; one normal ovary seen on scan (other obscured by bowel gas).
mPersonal history of bilateral breast cancer at ages 49 and 52 years; one sister had breast cancer at age 47 years; another sister had OC at age 71 years and breast
cancer at age 63 years; another sister had OC at age 53 years.
UK FOCSS Annual Screening Results
www.jco.org © 2012 by American Society of Clinical Oncology 5
128.40.156.97
Information downloaded from jco.ascopubs.org and provided by at UCL Library Services on December 5, 2012 from
Copyright © 2012 American Society of Clinical Oncology. All rights reserved.
Ta
bl
e
3.
S
cr
ee
ni
ng
P
er
fo
rm
an
ce
C
ha
ra
ct
er
is
tic
s
S
cr
ee
n
Ty
pe
To
ta
lS
cr
ee
ne
d
P
op
ul
at
io
n
(N

3,
56
3)
B
R
C
A
1
an
d
B
R
C
A
2
M
ut
at
io
n
C
ar
rie
rs
(n

53
8)
U
nk
no
w
n
M
ut
at
io
n
S
ta
tu
s
at
E
nr
ol
lm
en
t
(n

3,
06
5)
LS
M
ut
at
io
n
or
Fa
m
ily
H
is
to
ry
(n

99
)
P
re
va
le
nt
In
ci
de
nt

In
ci
de
nt
†
P
re
va
le
nt
In
ci
de
nt
‡
P
re
va
le
nt
In
ci
de
nt

In
ci
de
nt
†
P
re
va
le
nt
In
ci
de
nt
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
S
en
si
tiv
ity
O
cc
ul
t
FN
90
.0
55
.5
to
99
.8
81
.3
54
.3
to
96
.0
76
.5
50
.1
to
93
.2
85
.7
42
.1
to
99
.6
76
.9
46
.2
to
95
.0
N
A
§
91
.7
61
.5
to
99
.8
75
.0
19
.4
to
99
.4
10
0
29
.2
to
10
0
10
0
2.
5
to
10
0
O
cc
ul
t
TP
10
0
69
.2
to
10
0
87
.5
61
.7
to
98
.5
82
.4
56
.6
to
96
.2
10
0
59
.0
to
10
0
91
.7
61
.5
to
99
.8
N
A
§
10
0
73
.5
to
10
0
75
.0
19
.4
to
99
.4
10
0
29
.2
to
10
0
10
0
2.
5
to
10
0
S
pe
ci
fic
ity

99
.7
99
.5
to
99
.9
98
.9
98
.5
to
99
.2
98
.9
98
.5
to
99
.2
99
.2
98
.0
to
99
.8
99
.2
97
.9
to
99
.8
99
.7
99
.4
to
99
.8
99
.8
98
.3
to
99
.2
99
.8
98
.3
to
99
.2
10
0
96
.1
to
10
0
10
0
96
.1
to
10
0
P
P
V O
cc
ul
t
FN
42
.9
21
.8
to
66
.0
25
.5
14
.3
to
40
.0
25
.5
14
.3
to
40
.0
60
.0
26
.2
to
87
.8
71
.4
41
.9
to
91
.6
N
A
§
23
.9
12
.6
to
38
.8
23
.9
12
.6
to
38
.8
10
0
29
.2
to
10
0
10
0
2.
5
to
10
0
O
cc
ul
t
TP
45
.4
24
.4
to
67
.8
27
.0
15
.6
to
41
.0
27
.0
15
.6
to
41
.0
63
.6
30
.1
to
89
.1
73
.3
44
.9
to
92
.2
N
A
§
25
.5
14
.0
to
40
.3
25
.5
14
.0
to
40
.3
10
0
29
.2
to
10
0
10
0
2.
5
to
10
0
N
P
V O
cc
ul
t
FN
10
0
99
.8
to
10
0
99
.9
99
.8
to
10
0
99
.9
99
.7
to
10
0
99
.8
98
.9
to
10
0
99
.4
98
.2
to
99
.9
99
.9
99
.8
to
10
0
99
.9
99
.7
to
10
0
10
0
99
.8
to
10
0
10
0
96
.1
to
10
0
10
0
96
.1
to
10
0
O
cc
ul
t
TP
10
0
99
.9
to
10
0
99
.9
99
.8
to
10
0
99
.9
99
.8
to
10
0
10
0
99
.3
to
10
0
99
.6
98
.5
to
10
0
99
.9
99
.8
to
10
0
10
0.
00
99
.9
to
10
0
10
0
99
.8
to
10
0
10
0
96
.1
to
10
0
10
0
96
.1
to
10
0
S
cr
ee
n
Ty
pe
P
rio
r
S
tu
dy
fo
r
C
om
pa
ris
on
2
4
¶
O
cc
ul
t
S
ta
tu
s
N
o.
of
C
an
ce
rs
S
en
si
tiv
ity
S
pe
ci
fic
ity
P
P
V
N
P
V
To
ta
l
P
re
va
le
nt
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
%
95
%
C
I
In
ci
de
nt
pl
us
pr
ev
al
en
t
O
cc
ul
t
ex
cl
ud
ed
7
2
42
14
to
70
99
98
to
99
23
5
to
40
99
99
to
10
0
In
ci
de
nt
pl
us
pr
ev
al
en
t
O
cc
ul
t
FN
12
2
71
38
to
11
99
98
to
99
23
5
to
40
10
0
10
0
to
10
0
A
bb
re
vi
at
io
ns
:
FN
,
fa
ls
e
ne
ga
tiv
e;
LS
,
Ly
nc
h
sy
nd
ro
m
e;
N
A
,
no
t
ap
pl
ic
ab
le
;
N
P
V
,
ne
ga
tiv
e
pr
ed
ic
tiv
e
va
lu
e;
P
P
C
,
pr
im
ar
y
pe
rit
on
ea
lc
an
ce
r;
P
P
V
,
po
si
tiv
e
pr
ed
ic
tiv
e
va
lu
e;
TP
,
tr
ue
po
si
tiv
e.

E
xc
lu
di
ng
P
P
C
.
†I
nc
lu
di
ng
P
P
C
.
‡N
o
P
P
C
s
in
B
R
C
A
ca
rr
ie
rs
oc
cu
rr
ed
w
ith
in
1
ye
ar
of
pr
io
r
sc
re
en
.
§N
ot
ap
pl
ic
ab
le
be
ca
us
e
no
pr
ev
al
en
t
ca
nc
er
s
oc
cu
rr
ed
in
un
kn
ow
n
m
ut
at
io
n
st
at
us
gr
ou
p.
O
cc
ul
t
ca
nc
er
s
no
t
ap
pl
ic
ab
le
(s
pe
ci
fic
ity
do
es
no
t
de
pe
nd
on
fa
ls
e-
ne
ga
tiv
e
or
tr
ue
-p
os
iti
ve
ra
te
).
¶
O
nl
y
la
rg
e
pr
io
r
st
ud
y
to
ou
r
kn
ow
le
dg
e
w
ith
da
ta
re
po
rt
ed
in
a
fa
sh
io
n
th
at
al
lo
w
s
so
m
e
co
m
pa
ris
on
of
pe
rf
or
m
an
ce
ch
ar
ac
te
ris
tic
s
w
ith
ou
r
st
ud
y.
Rosenthal et al
6 © 2012 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
128.40.156.97
Information downloaded from jco.ascopubs.org and provided by at UCL Library Services on December 5, 2012 from
Copyright © 2012 American Society of Clinical Oncology. All rights reserved.
Intervals in Screening and Surgical Investigation
Table 4 shows delays in annual screens detecting incident OC/
FTCs and intervals between abnormal results and diagnosis in preva-
lent and incident cases. Reasons for delays included: temporarily
leaving the United Kingdom, assuming abnormal results were the
result of endometriosis, and women’s reluctance to undergo surgery.
DISCUSSION
The present study is the first large prospective high-risk population
screening study reported to our knowledge. The other large ongoing
studies are the US Cancer Genetics Network and Gynaecologic On-
cology Group 19925 studies. The strengths of our study are its size,
reliable follow-up via multiple routes, and analysis of intervals in
screening and surgical investigation not previously studied in this
context. Its limitations are the lack of an enforced screening/manage-
ment protocol, incomplete documentation confirming relatives’ can-
cers, and incomplete screening results for those not undergoing
surgery. This prevents reliable estimates of repeat testing rates. Finally,
there was no mandatory pathology protocol for RRSO specimens,
possibly explaining the low occult cancer prevalence (0.8%).
Previously, a meta-analysis22 suggested that annual screening
might not provide adequate sensitivity for early-stage disease. How-
ever, when duplicate cases were excluded, 14 (45.2%) of 31 detected
caseswere stage I or II.26 Subsequently, additional cohort studieswere
reported separately24,27-31 and as a pooled analysis.32 We reanalyzed
these data33 and found a borderline significant (P .046) improve-
ment in the stage distribution of screen-detectedBRCA1/2-associated
cancers (52.6%of incident v19.0%ofprevalent cancerswere stage I or
II). Our study suggests that screening in the year before diagnosis
reduces the proportion of patients diagnosed at stage IIIc but does
not increase theproportiondiagnosedat stage I.This is consistentwith
the hypothesis that high-grade serousOCundergoes early transcoelo-
mic spread.34 The nonsignificantly higher optimal debulking rate and
nonsignificant trend to increased survival in those screened in the year
before diagnosis suggest that screening might have an effect on sur-
vival, but they do not prove screeningwill reducemortality. In partic-
ular, there could be a lead-time effect, with longer survival resulting
solely from earlier diagnoses rather than screening efficacy. In addi-
tion, this analysis compares small nonrandomizedgroupsdetermined
by screening interval, so there could be other important differences
between them.
We found 66.7% of the prevalent cases were early stage. This
could be chance, or it could reflect the fact that three of five stage I
cancers occurred in LS mutation carriers. The prognosis of LS OC is
better than that associated with BRCA1/2 mutations,35 possibly be-
cause presentation occurs earlier.36 We therefore speculate that LS-
associated tumors have a longer sojourn time, explaining the high
proportion of early-stage disease in the prevalence screen. Given that
33 of 37 OC/FTC/PPCs occurred in women with a predisposingmu-
tation, clearly mutation carriers are at highest cancer risk. However,
first-degree relatives of cancer-affected individuals from untested
high-risk families should also be considered high risk and counseled
accordingly.37Where anunaffected relative is theonly familymember
tested, and she is mutation negative, then her risk would be consider-
ably lower than that of a mutation carrier, but not as low as that of a
woman testing negative for a relative’s known pathogenic mutation.
We are not aware of any data on OC incidence in mutation-negative
women from otherwise untested high-risk families. However, given
ourfindings,we speculate that theymaynot be at sufficiently high risk
to justify familial OC screening.
The performance characteristics of annual screening were en-
couraging. The incident sensitivity ( 80%) was higher than that
previously reported24 (Table 3). However, the proportion of early-
stage disease was disappointing (two of 13 incident screen-detected
cases were stage I), supporting the current assertion in the National
Comprehensive Cancer Network guideline38 that annual screening is
ineffective inhigh-riskwomen.Thehigh incidentPPV(similar to that
previously reported24) means that only four women underwent sur-
gery for each case of cancer detected.As expected, the PPVwas greater
inmutation carriers than in those of unknownmutation status. Only
0.6% underwent screening-related surgery prompted by nonnormal
but clinically nonsuspicious screening results.
The high negative predictive value is relevant to this population
of women, who may undergo screening to delay RRSO to complete
childbearing or delay surgically inducedmenopause. Althoughmuch
of the high negative predictive value derives from the low annual
incidence of OC/FTC even in BRCA1/BRCA2 mutation carriers, the
knowledge that normal test results provide 99.9% (99.4% in known
mutation carriers) probability a woman will not be diagnosed with
OC in the next year should help decision making regarding timing
of RRSO.
Many cancers had long intervals between annual screens and/or
between abnormal results and diagnosis. The United Kingdomman-
dates a 62-day maximum acceptable interval from suspected cancer
referral to treatment.39 However, this limit was not consistently deliv-
ered nationally until 2006,40 whenUKFOCSS had been running for 4
years. In this high-risk population, it is essential that screening is not
delayed, that abnormal results are assumed to represent possible can-
cer, and that the threshold for rapid follow-up tests or surgery is set
much lower than in the general population. Stricter protocols may
increase the false-positive rate, but the PPV achieved was suffi-
ciently high to remain acceptable even if some increase in false
positives occurs.
Given the delays we observed, we speculate that rigorous adher-
ence to screening schedules and swifter action on abnormal results
might result in earlier stage at diagnosis. Phase II of UK FOCSS has
implemented the following modifications: one, the screening fre-
quency has been increased to once every 4months; two, the threshold
for and timing of repeat tests is protocol driven; three, CA125 is
Table 4. Screening and Surgery Intervals in Screen-Detected Cancers
Screen Type
No. of
Cancers
Screen Delay
(days)
Surgery Interval
(days)
Composite
Interval (days)
Median Range Median Range Median Range
Prevalent 9 NA 79 20-141 NA
Incident screen
detected 13 88 6-737 79 15-184 154 27-875
Stage I/II 4 231 49-737 50 19-138 160 27-875
Stage III 9 78 6-236 96 15-184 154 68-413
Abbreviation: NA, not applicable.
Prevalent screen is the first screen and cannot be delayed. Calculation of
composite delay for prevalent cases is not appropriate.
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assayed in a single laboratory to reduce interassay variability; four,
serial CA125 values are analyzed by a risk of OC algorithm,41 which
has demonstrated superior performance to CA125 when used as a
cutoff42; and five, collaborators are prompted to organize scans and
referrals via an Internet-based database, modeled on the successful
UKCTOCS (United Kingdom Collaborative Trial of Ovarian Cancer
Screening) database.43 It is hoped that these changes will optimize
early-stage OC detection in the high-risk population. If this is
achieved, and ifUKCTOCSdemonstrates reducedgeneral population
OC mortality, then high-risk women wishing to delay RRSO can be
offered a risk-minimizing screening strategy before surgery. Until
then, RRSO remains the only provenmethod of preventingmortality
fromOC/FTC.
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Appendix
Family History/Mutation Eligibility Criteria
Eligibilitywasdeterminedas follows:Participantswereknowncarriers of oneof theOCpredisposinggenes (BRCA1, BRCA2, MLH1,
MSH2, MSH6, PMS1, PMS2) or first-degree relatives (mother, sister, daughter) of an affected member of a high-risk family. High-risk
families were those fulfilling any of the following criteria:
● The family contained two or more individuals with ovarian cancer (OC) who were first-degree relatives
● The family contained one individual with OC and one individual with breast cancer diagnosed at age  50 years who were
first-degree relatives
● The family contained one individual with OC and two individuals with breast cancer diagnosed at age  60 years who were
connected by first-degree relationships
● The family containedanaffected individualwith amutationofoneof theknownOCpredisposinggenes (BRCA1,BRCA2,MLH1,
MSH2, MSH6, PMS1, PMS2)
● The family contained three individuals with colorectal cancer, at least one of whomwas diagnosed at age 50 years as well as one
individual with OC, and all of these individuals were connected by first-degree relationships
● The first three criteria could be modified where paternal transmission occurred (ie, families in which affected relatives
were related by second degree through an unaffected intervening male relative and in which the proband had an
affected sister were eligible)
In addition, whenwomen did not fall within these inclusion criteria, but the recruiting center felt that they had a lifetime risk of OC
of 10%, the study clinical geneticist (J.M.) reviewed the pedigree and documentation of diagnoses to determine eligibility.
UItrasound Classification System
Ovarian size. Ovarian diameter was measured in three dimensions and used to calculate ovarian volume using the formula for an
ellipsoid (d1 d2 d3 0.523).
Ovarian morphology. Ovarian echogenicity was assessed for the presence of cysts, cyst septae, solid areas, and papillations.
Morphology was classified as follows:
● Normal: uniform ovarian echogenicity or one or both ovaries not visualized despite a good view of the pelvic side wall (ie, iliac
vessels visualized)
● Equivocal: single ormultiple simple cysts (ie, cystswithno septae or papillations and thinwallswith a regular internal outline) and
polycystic ovaries with classical scan features of small peripheral cysts and increased stromal echogenicity
● Suspicious: all complex morphology (nonuniform ovarian echogenicity) excluding that described under equivocal
All suspicious scans and those with an ovarian volume 60mL were considered abnormal.
Rosenthal et al
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Table A1. UK FOCSS Collaborators, Data Monitoring Committee, and Trial Steering Committee Members
Center Collaborators
Belfast Patrick Morrison, Hans Nagar
Birmingham James Nevin
Bristol Robert Anderson, John Murdoch
Cambridge Robin Crawford
Cardiff Jonathon Gray, Mark Rogers
Cheltenham and Gloucester Robert Gornall
Chester Sharon Rowe
Cumberland Sheila Pearson
Derby Ian Scott, Howard Jenkins
Durham Partha Sengupta
Dundee David Goudie
East Kent Andy Nordin
Edinburgh Mary Porteous
Gateshead Richard Edmondson
Glasgow Rosemary Davidson
Guys Gabriella Pichert, Chris Jacobs
Hammersmith Sadaf Ghaem-Maghami
Hull Mike Lind, David Poole
Kettering Robert Haughney
Leeds Carol Chu, Roger Rand, Richard Hutson, Ian Beck, Cheng Choy
Leicester Richard Trembath, Quentin Davies
Lincoln Martin Lamb
Liverpool Carol Bejamin
London Northwest Huw Dorkins
London UCLH Usha Menon, Michelle Johnson
Manchester Gareth Evans
Mid Essex Colin Partington, Christopher Goodfellow
Milton Keynes Christopher B. Lynch
Newcastle Fiona Douglas
North England Paul Brennan, Mary George, John McDonald
North Staffordshire Vijay Menon
North Wales Alex Murray, Philip Banfield, Simon Leeson, Philip Toon
Northampton Sue Price, Alistair Duncan
Nottingham Susan Ritchie, Karin Williamson
Oxford Cyril Chapman, Anneke Lucassen, Lucy Side, Lisa Walker
Peninsula Carole Brewer, Tony Falconer, Tito Lopes
Sheffield Jackie Cook
Somerset West Robert Fox
Southampton Diana Eccles
St George’s London Shirley Hodgson
Surrey Gareth Beynon
Swansea Alex Murray, Omar Freites
The Royal Marsden, London Rosalind Eeles
Wycombe/Stoke Damien Eustace
West Kent Andreas Papadopoulos
Data Monitoring Committee Shehla Mohammed, Mahesh Parmar (chair), Karina Reynolds
Trial Steering Committee Louise Bayne (lay member), Kate Brain, Derek Cruikshank, Stephen Duffy, Diana Eccles, Lindsay Fraser, Ian Jacobs, Usha
Menon, Julietta Patnick (chair), Adam Rosenthal, Steve Skates
Abbreviations: UK FOCSS, United Kingdom Familial Ovarian Cancer Screening Study; UCLH, University College London Hospitals.
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Annual screen TVS and CA125
Abnormal or equivocal scan or elevated CA125
Abnormal scan or
equivocal scan and elevated
CA125
Equivocal scan and
normal CA125
Normal scan and
normal CA125
Normal scan and
elevated CA125
Normal scan and elevated CA125
Rule out other causes of elevated CA125
gnineercs launna ot nruteRtsigolocno cigolocenyg deman ot larrefeR
Repeat TVS + CA125 in
6-10* weeks
Repeat TVS + CA125 in 6-10* weeks
Normal scan and normal CA125
Fig A1. Annual transvaginal ultrasound scan (TVS) and CA125 screening. Normal, equivocal, and abnormal scan definitions provided in Appendix. Elevated CA125: 
35 and  30 IU/mL in premenopausal and postmenopausal women, respectively. (*) Earlier intervention if clinical suspicion warrants. These represent guidelines only;
clinical management of the women remained at the discretion of collaborating local gynecologists. When an elevated CA125 or non-normal scan was found at an annual
screen, it was the local gynecologist’s decision whether the test should be repeated before surgical investigation. If the test was repeated, the interval before repeat
testing was also at his or her discretion. The study guidelines recommended that intervention be considered earlier if there was clinical suspicion of cancer to discourage
unnecessary delays when screening test results were clearly concerning.
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